Vanguard Global Advisers
ZVRA icon

Vanguard Global Advisers’s Zevra Therapeutics ZVRA Stock Holding History

Vanguard Global Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290K Sell
20,246
-4,000
-16% -$44.5K ﹤0.01% 2347
2026
Q1 		$226K Buy
+24,246
New +$219K ﹤0.01% 2378

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers's ZVRA Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Zevra Therapeutics (ZVRA) stake by 16% in Q2 2026, selling an estimated $44.5K and leaving 20,246 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #2347.

Vanguard Global Advisers first reported a position in ZVRA in Q1 2026 and has held it in 2 quarters since. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Vanguard Global Advisers held 20,246 shares of Zevra Therapeutics worth $290K as of Q2 2026.
  • Vanguard Global Advisers sold 4,000 Zevra Therapeutics shares in Q2 2026, an estimated $44.5K.
  • Zevra Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2347 holding.
  • Vanguard Global Advisers first reported a position in Zevra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.